. 2022 Apr 1;17(4):e0266243. doi: 10.1371/journal.pone.0266243

Table 1. Characteristics of the included studies.

Author, year	Location (sites number)	Study design	Study period	Groups	Number of patients	Age in years, Mean ± SD	Male ratio, %	Roxadustat dose	Study duration	Phase
Akizawa et al. 2019 [32]	Japan (32)	Double-blinded RCT	2013–2015	Roxadustat	80	64.4 ± 8.7	48.80%	(50 mg,70 mg, and 100 mg) TIW	24 weeks	2
Akizawa et al. 2019 [32]	Japan (32)	Double-blinded RCT	2013–2015	Placebo	27	61.9 ± 10.6	40.70%	(50 mg,70 mg, and 100 mg) TIW	24 weeks	2
Akizawa et al. 2021 [14]	Japan (71)	Open-label RCT	2017–2020	Roxadustat	131	68.9 ± 11.6	63.40%	(70mg or 100mg) TIW	52 weeks	3
Akizawa et al. 2021 [14]	Japan (71)	Open-label RCT	2017–2020	DA	131	70.9 ± 10.2	57.30%	(70mg or 100mg) TIW	52 weeks	3
Barratt et al. 2021 [15]	Europe (200)	Open-label RCT	2014–2018	Roxadustat	323	66.8 ± 13.6	44.90%	(Weight 45 to 70 kg, 70 mg; weight >70 to 160 kg, 100 mg) TIW	104 weeks	3
Barratt et al. 2021 [15]	Europe (200)	Open-label RCT	2014–2018	DA	293	65.7 ± 14.4	44%		104 weeks	3
Besarab et al. 2015 [33]	United States (29)	Single-blind RCT	2008–2010	Roxadustat	88	64	37.50%	(0.7, 1, 1.5 or 2 mg/kg) BIW or TIW	4 weeks	2a
Besarab et al. 2015 [33]	United States (29)	Single-blind RCT	2008–2010	Placebo	28	68.6	57.10%	(0.7, 1, 1.5 or 2 mg/kg) BIW or TIW	4 weeks	2a
Chen et al. 2017 [29]	China (11)	Double-blinded RCT	2011–2012	Roxadustat	61	48.9 ± 13.8	29.50%	low (1.1–1.75 mg/kg) or high (1.50–2.25 mg/kg) TIW	8 weeks	2
Chen et al. 2017 [29]	China (11)	Double-blinded RCT	2011–2012	Placebo	30	51.4 ± 11.9	26.70%	low (1.1–1.75 mg/kg) or high (1.50–2.25 mg/kg) TIW	8 weeks	2
Chen et al. 2019 [30]	China (29)	Double-blinded RCT	2015–2016	Roxadustat	101	54.7 ± 13.3	36%	(Weight 40 to <60 kg, 70mg; weight ≥60 kg, 100mg) TIW	8 weeks	3
Chen et al. 2019 [30]	China (29)	Double-blinded RCT	2015–2016	Placebo	51	53.2 ± 13.1	39%	(Weight 40 to <60 kg, 70mg; weight ≥60 kg, 100mg) TIW	8 weeks	3
Coyne et al. 2021 [28]	United States, South America, Australia, New Zealand, and Asia (163)	Double-blinded RCT	2012–2018	Roxadustat	616	64.9 ± 12.6	39.10%	(Weight 45 to <70 kg, 70mg; weight ≥70 kg, 100mg) TIW	28–52 weeks	3
Coyne et al. 2021 [28]		Double-blinded RCT	2012–2018	Placebo	306	64.8 ± 13.2	43.50%	(Weight 45 to <70 kg, 70mg; weight ≥70 kg, 100mg) TIW	28–52 weeks	3
Fishbane et al. 2021 [34]	25 Countries (385)	Double-blinded RCT	2014–2018	Roxadustat	1384	60.9 ± 14.7	40.80%	70mg TIW	28–52 weeks	3
Fishbane et al. 2021 [34]	25 Countries (385)	Double-blinded RCT	2014–2018	Placebo	1377	62.4 ± 14.1	43.80%	70mg TIW	28–52 weeks	3
Shutov et al. 2021 [16]	Different countries, mainly from Europe (138)	Double-blinded RCT	2013–2017	Roxadustat	391	58.25 ± 19.91	43.20%	(Weight 45 to ≤70 kg, 70mg; weight >70 to ≤ 160 kg, 100mg) TIW	52–104 weeks	3
Shutov et al. 2021 [16]	Different countries, mainly from Europe (138)	Double-blinded RCT	2013–2017	Placebo	203	60.5 ± 18.46	48.80%		52–104 weeks	3

Continuous variables are expressed in mean ± standard deviation.

RCT = randomized control trial; DA = darbepoetin alfa; TIW = three times a week; DIW = two times a week; SD: standard deviation.